Chemistry: natural resins or derivatives; peptides or proteins; – Peptides of 3 to 100 amino acid residues – 8 to 10 amino acid residues in defined sequence
Reexamination Certificate
2006-01-24
2006-01-24
Kemmerer, Elizabeth (Department: 1646)
Chemistry: natural resins or derivatives; peptides or proteins;
Peptides of 3 to 100 amino acid residues
8 to 10 amino acid residues in defined sequence
C530S300000, C530S323000, C530S324000, C530S327000, C530S317000, C435S069500, C435S070100, C435S071100, C435S071200, C435S325000, C435S252300, C435S320100, C435S091200
Reexamination Certificate
active
06989435
ABSTRACT:
Isolated and purified chemokine peptides, variants, and derivatives thereof, as well as chemokine peptide analogs, are provided.
REFERENCES:
patent: 4108855 (1978-08-01), Magó nee Karácsony et al.
patent: 4724232 (1988-02-01), Rideout et al.
patent: 4737580 (1988-04-01), Twardzik et al.
patent: 4774318 (1988-09-01), Marquardt et al.
patent: 5079228 (1992-01-01), Cohen et al.
patent: 5155038 (1992-10-01), Eyal et al.
patent: 5190918 (1993-03-01), Deutch et al.
patent: 5190920 (1993-03-01), Eyal et al.
patent: 5192744 (1993-03-01), Bouck et al.
patent: 5202118 (1993-04-01), Gillis et al.
patent: 5212073 (1993-05-01), Rollins et al.
patent: 5248666 (1993-09-01), Twardzik et al.
patent: 5302384 (1994-04-01), Gimbrone, Jr. et al.
patent: 5357041 (1994-10-01), Roberts et al.
patent: 5401651 (1995-03-01), Walz
patent: 5426100 (1995-06-01), Deutch et al.
patent: 5458874 (1995-10-01), Pereira et al.
patent: 5459128 (1995-10-01), Rollins et al.
patent: 5474983 (1995-12-01), Kuna et al.
patent: 5556757 (1996-09-01), Alstyne et al.
patent: 5571713 (1996-11-01), Lyle et al.
patent: 5578714 (1996-11-01), Pogo et al.
patent: 5589458 (1996-12-01), Jameson et al.
patent: 5597578 (1997-01-01), Brown et al.
patent: 5605671 (1997-02-01), Lyle et al.
patent: 5627156 (1997-05-01), Talmadge
patent: 5627265 (1997-05-01), Frazier et al.
patent: 5645837 (1997-07-01), Jameson et al.
patent: 5646117 (1997-07-01), Matsushima et al.
patent: 5650150 (1997-07-01), Gillies
patent: 5661132 (1997-08-01), Eriksson et al.
patent: 5663294 (1997-09-01), Colman et al.
patent: 5684032 (1997-11-01), Elliott et al.
patent: 5705360 (1998-01-01), Rollins et al.
patent: 5707814 (1998-01-01), Levy et al.
patent: 5707815 (1998-01-01), Charo et al.
patent: 5770609 (1998-06-01), Grainger et al.
patent: 5811449 (1998-09-01), Medford et al.
patent: 5817911 (1998-10-01), Williams et al.
patent: 5824299 (1998-10-01), Luster et al.
patent: 5824551 (1998-10-01), Damme et al.
patent: 5824647 (1998-10-01), Postlethwaite et al.
patent: 5827821 (1998-10-01), Pierschbacher et al.
patent: 5831032 (1998-11-01), Schraufstatter et al.
patent: 5871740 (1999-02-01), Smith
patent: 5877276 (1999-03-01), Talmadge
patent: 5908829 (1999-06-01), Kelly
patent: 5955485 (1999-09-01), De Brabander et al.
patent: 5955492 (1999-09-01), Thompson et al.
patent: 27 10 246 (1977-09-01), None
patent: 0 281 363 (1988-09-01), None
patent: 0807439 (1997-11-01), None
patent: 36-14610 (1961-08-01), None
patent: 06-025288 (1994-02-01), None
patent: 7-67689 (1995-03-01), None
patent: 9-255570 (1996-03-01), None
patent: 86/04334 (1986-07-01), None
patent: 90/07863 (1990-07-01), None
patent: 91/08483 (1991-06-01), None
patent: 91/17179 (1991-11-01), None
patent: 92/04372 (1992-03-01), None
patent: WO-92/14455 (1992-09-01), None
patent: 92/20372 (1992-11-01), None
patent: 93/11159 (1993-06-01), None
patent: 94/11014 (1994-05-01), None
patent: 94/20512 (1994-09-01), None
patent: 95/05191 (1995-02-01), None
patent: 95/17420 (1995-06-01), None
patent: 95/17421 (1995-06-01), None
patent: WO 9520973 (1995-08-01), None
patent: 95/26982 (1995-10-01), None
patent: 96/20722 (1996-07-01), None
patent: 96/22371 (1996-07-01), None
patent: 96/29074 (1996-09-01), None
patent: 97/01350 (1997-01-01), None
patent: 97/12615 (1997-04-01), None
patent: 97/19173 (1997-05-01), None
patent: 97/21812 (1997-06-01), None
patent: 97/22698 (1997-06-01), None
patent: 97/24325 (1997-07-01), None
patent: 97/25427 (1997-07-01), None
patent: 97/29192 (1997-08-01), None
patent: 97/31098 (1997-08-01), None
patent: 97/32019 (1997-09-01), None
patent: 98/12324 (1998-03-01), None
patent: 92/04372 (1999-03-01), None
patent: WO-00/00821 (2000-01-01), None
Mikayama T. Molecular cloning and functional expression of a cDNA encoding glycosylation-inhibiting factor. Proc. Natl. Acad. Sci. USA vol. 90, pp. 10056-10060, 1993.
Voet et al. Biochemistry. 1990. John Wiley & Sons, Inc.. pp. 126-128 and 228-234.
Bowie et al (1990) Science vol. 247, pp. 1306-1310.
George et al., Macro molecular Sequencing & Synthesis Ch. 12, pp. 127-149, Alan R. Ligs, Inc. N.Y., 1988.
Cunningham et al. Science vol. 244, pp. 1081-1085, 1989.
Gong, J., et al., “RANTES and MCP-3 Antagonists Bind Multiple Chemokine Receptors”,The Journal of Biological Chemistry, 271, 10521-10527 (1996).
Shibata, Y. et al., “N-Alkylphtalimides: Structural Requirement of Thalidomidal Action on 12-0-Tetradecanoylphorbol-13-acetate Induced Tumor Necrosis Factor α Production by Human Leukemia HL-60 Cells”,Chem. Pharm. Bull., 43(1), 177-179 (1995).
Brunden et al., “pH-Dependent Binding of Synthetic β-Amyloid Peptides to Glycosaminoglycans”,J.Neurochem., 61, 2147-2154 (1993).
Karpus, W., et al., “Differential CC Chemokine-Induced Enhancement of T Helper Cell Cytokine Production”,The Journal of Immunology, 158, 4129-4136, (1997).
Maccarana et al., “Mode of Interaction Between Platelet Factor 4 and Heparin”,Glycobiology, 3, 271-277 (1993).
McFadden, G., et al., “Commentary: New Strategies for Chemokine Induction and Modulation; You Take the High Road and I'll Take the Low Road”,Biochemical Pharmacology, 54, 1271-1280, (1997).
Mehlop, P.D., et al., “Allergen-induced Bronchial Hyperreactivity and Eosinophilic Inflammation Ocur in teh Absence of IgE in a Mouse Model of Asthma”,Proceedings of the National Academy of Sciences USA, 94, 1344-1349, (1997).
Sekiguchi et al., “Binding of Fibronectin and Its Proteolytic Fragments to Glycosaminoglycans”,J. Biol. Chem., 258, 14359-14365 (1983).
Waltenberger, J., “Modulation of Growth Factor Action—Implications for the Treatment of Cardiovascular Diseases”,Circulation, 96, 4083-4094, (1997).
Alkhatib et al., “HIV-1 Coreceptor Activity of CCR5 and Its Inhibition by Chemokines: Independence from G Protein Signaling and Importance of Coreceptor Downmodulation”,Virology, 234, 340-348 (1997).
Auer et al., “Crystallization and Preliminary X-ray Crystallographic Study of Interleukin-8”,FEBS Letters, 265, 30-32 (1990).
Bacon et al., “Activation of Dual T Cell Signaling Pathways by the Chemokine RANTES”,Science, 269, 1727-1730 (1995).
Baldwin et al., “Crystal Structure of Interleukin 8: Symbiosis of NMR and Crystallography”,Proc. Natl. Acad. Sci. USA, 88, 502-506 (1991).
Baldwin et al., “Crystallization of Human Interleukin-8”,The Journal of Biological Chemistry, 265, 6851-6853 (1990).
Beck-Schimmer et al., “Hyaluronan Induces Monocyte Chemoattractant Protein-1 Expression in Renal Tubular Epithelial Cells”,Journal of the American Society of Nephrology, 9, 2283-2290 (1988).
Chakravarty et al., “Lysine 58 and Histidine 66 at the C-terminal alpha-Helix of Monocyte Chemoattractant Protein-1 are Essential for Glycosaminoglycan Binding”,The Journal of Biological Chemistry, 273, 29641-29647 (1988).
Chung et al., “The Three-Dimensional Solution Structure of RANTES”,Biochemistry, 34, 9307-9314 (1995).
Clore et al., “Comparison of the Solution Nuclear Magnetic Resonance and Crystal Structures of Interleukin-8”,J. Mol. Biol., 217, 611-620 (1991).
Cocchi et al., “The V3 Domain of the HIV-1 gp120 Envelope Glycoprotein is Critical for Chemokine-Mediated Blockade of Infection”,Nature Medicine, 11, 1244-1247 (1996).
Fairbrother et al., “The Solution Structure of Melanoma Growth Stimulating Activity”,Journal of Molecular Biology, 242, 252-270 (1994).
Gong et al., “Antagonist of Monocyte Chemoattractant Protein 1 (MCP-1) Inhibits Arthritis in the MRL-lp4 Mouse Model”,Journal of Experimental Medicine, 186, 131-137 (1997).
Gong et al., “Antagonists of Monocyte Chemoattractant Protein 1 Identified by Modification of Functionally Critical NH2-terminal Residues”,J. Exp. Med, 181, 631-640 (1995).
Gosling et al., “Molecular Uncoupling of C-C Chemokine Receptor 5-Induced Chemotaxis and Signal Transduction from HIV-1 C
Grainger David J.
Tatalick Lauren Marie
Cambridge University Technical Services Ltd.
Kemmerer Elizabeth
Murphy Joseph F.
Schwegman Lundberg Woessner & Kluth P.A.
LandOfFree
Compounds and methods to inhibit or augment an inflammatory... does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Compounds and methods to inhibit or augment an inflammatory..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Compounds and methods to inhibit or augment an inflammatory... will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-3549809